2022
Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data
Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. Frontiers In Cardiovascular Medicine 2022, 9: 829553. PMID: 35369354, PMCID: PMC8964995, DOI: 10.3389/fcvm.2022.829553.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMagnetic resonance imagingExtracellular volumeEarly detectionImmune checkpoint inhibitionWall motion abnormalitiesCancer therapyMechanisms of cardiotoxicityTyrosine kinase inhibitorsCurrent imaging modalitiesAssessment of functionCardioprotective medicationsCardiotoxic eventsMolecular radiotracersCardiovascular outcomesMolecular imagingCheckpoint inhibitionNovel cancer therapiesOncologic therapyCancer mortalityMyocardial infarctionMotion abnormalitiesCardiac metabolismCardiotoxicityResonance imagingTherapy
2021
Adverse cardiovascular events in patients treated with mogamulizumab
Kwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. PMID: 38559371, PMCID: PMC10978139, DOI: 10.1016/j.ahjo.2021.100049.Peer-Reviewed Original ResearchAdverse cardiovascular eventsMogamulizumab therapyCardiovascular eventsHeart failureAdverse outcomesNon-cardiovascular eventsWorld Health Organization databaseFatal adverse outcomesT-cell leukemiaACE occurrenceMogamulizumab treatmentNew hypertensionAdverse eventsCardiac deathVentricular arrhythmiasFatal outcomeUnique patientsCardiovascular toxicityMyocardial infarctionImportant treatmentHigh mortalityPatientsMogamulizumabTherapyOrganization database